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Human papillomavirus (HPV) is the etiologic risk factor for cervi-
cal cancer. Some studies have suggested an association with a subset 
of lung tumors, but the etiologic link has not been firmly estab-
lished. We performed an international pooled analysis of cross-
sectional studies (27 datasets, n = 3249 patients) to evaluate HPV 
DNA prevalence in lung cancer and to investigate viral presence 
according to clinical and demographic characteristics. HPV16/18 
were the most commonly detected, but with substantial variation 
in viral prevalence between geographic regions. The highest preva-
lence of HPV16/18 was observed in South and Central America, 
followed by Asia, North America and Europe (adjusted prevalence 
rates = 22, 5, 4 and 3%, respectively). Higher HPV16 prevalence 
was noted in each geographic region compared with HPV18, except 
in North America. HPV16/18-positive lung cancer was less likely 
observed among White race (adjusted odds ratio [OR] = 0.33, 95% 
confidence interval [CI] = 0.12–0.90), whereas no associations were 
observed with gender, smoking history, age, histology or stage. 
Comparisons between tumor and normal lung tissue show that 
HPV was more likely to be present in lung cancer rather than nor-
mal lung tissues (OR = 3.86, 95% CI = 2.87–5.19). Among a subset 
of patients with HPV16-positive tumors, integration was primar-
ily among female patients (93%, 13/14), while the physical status 
in male cases (N = 14) was inconsistent. Our findings confirm that 
HPV DNA is present in a small fraction of lung tumors, with large 
geographic variations. Further comprehensive analysis is needed to 
assess whether this association reflects a causal relationship.
Introduction
Lung cancer is the third most common cancer in men and women of 
all races and the leading cause of cancer death in the United States and 
worldwide. Cigarette smoking is the primary risk factor and accounts 
for ~85% of all lung cancer cases. Other less prevalent risk factors are 
genetic factors, family history of lung cancer and exposures to radon, 
asbestos, arsenic, diesel exhaust and some forms of silica and chro-
mium. Human papillomavirus (HPV) is a small non-enveloped DNA 
tumor virus of the family Papillomaviridae and is the established 
etiological agent of genital warts, cervical cancer and a proportion of 
cancers of the vulva, vagina, penis, anus and oropharynx (1,2). More 
than 100 different genotypes have been identified, and types 16 and 
18 are the most common oncogenic types, leading to the development 
of ~70% of all cervical carcinomas.
In 1979, Syrjänen first hypothesized that certain types of HPV 
are responsible for causing cancer in the lung (3). In the last three 
decades, the number of reports suggesting an association between 
HPV and lung cancer has increased tremendously. A review of HPV 
in 2468 lung cancer cases was first published in 2002 and showed 
that, using morphological, immunohistochemical and HPV DNA 
detection methods (4), ~22% of the cases analyzed contained HPV. 
This meta-analysis was updated in 2007 and reported a prevalence of 
24.5%, but considerable heterogeneity was observed between stud-
ies (5). In our meta-analysis in 2009 (6), we also identified a wide 
variation in the prevalence of HPV in lung cancer tissues, despite the 
fact that only studies utilizing PCR-based methods for HPV detection 
were included in order to reduce the heterogeneity between studies. 
Nevertheless, HPV16 and 18 were the two most common genotypes 
detected in lung tumors, and a higher prevalence of HPV16 and 18 
was noted in Asian populations compared with European populations. 
In 2012, the most recent meta-analysis was published and reported 
that the variability of HPV prevalence may be due to differences in 
geographical study origin and histological types of lung cancer rather 
than the method of HPV detection (7). However, meta-analyses find-
ings to date have limitations because important characteristics such as 
Abbreviations: AdjPr, adjusted prevalence; CI, confidence interval; FFPE, 
formalin fixed paraffin embedded; HPV, human papillomavirus; OR, odds 
ratio; SCC, squamous cell carcinoma.
†These authors contributed equally to this work and should be considered 
co-first authors.
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gender, tumor stage and smoking status of HPV-positive lung cancer 
patients have not been taken into account. To address these limitations, 
we have conducted an international, multi-institutional, pooled analy-
sis of studies to further analyze the characteristics of cases observed 
with HPV16/18 DNA with particular emphasis on race, gender, smok-
ing status, tumor stage as well as histology of the cancers. The most 
recent meta-analysis has been updated (7); prevalence rates of HPV in 
lung tumors by geographic region, adjusted for age, gender, smoking 
status and tumor stage are presented. Because the majority of studies 
to date have been conducted in Asian and European populations, com-
parisons of demographic and clinical characteristics of HPV-positive 
lung cancer cases were also made between North American cases and 
the rest of the world.
Materials and methods
Literature review and data extraction
A flow diagram that summarizes the literature review process and selection of 
datasets for inclusion in the pooled analysis is described in Figure 1. A biblio-
graphic search was carried out in the PubMed database to identify the studies 
that evaluated HPV status of primary lung tumors published up to July 2013. 
The search strategy used was: (HPV OR HPV) AND (lung OR bronchogenic) 
AND (cancer OR carcinoma). A manual review of the bibliographic references 
cited in the selected papers was also undertaken to retrieve papers that might 
have been missed in the initial search. From this search, 90 publications were 
identified. When the data were reported from the same cohort (8–30), only the 
most recent publication or one that had the larger cohort of lung cancer cases 
was included (10,13,14,17,20,21,25,26,30). Two publications had overlapping 
squamous cell carcinoma (SCC) cases (8,9) but only one reported data for 
adenocarcinoma cases (9). Therefore, although counted as a single study, both 
publications were included. To ensure that the larger cohort was included, the 
SCC data were extracted from one publication (8) and the adenocarcinoma 
data from the other (9). The majority of studies to date were conducted in 
Asian and European populations. Data from two published abstracts (31,32) 
and two unpublished datasets (E.Taioli et al. and A.Zaravinos et al., unpub-
lished results) have also been included in this pooled analysis. These cases 
were recruited from three medical institutions in the United States and one 
from Greece. This resulted in 79 published studies and 2 unpublished studies, 
which include 7440 lung cancer cases. Sixteen studies also reported the preva-
lence of HPV in non-tumor lung tissues (i.e. in adjacent normal tissues from 
lung cancer cases or in lung tissues from non-cancer cases) (13,17,20,25,33–
44). These data are included as a subset analysis comparing HPV prevalence 
between tumor and normal lung tissue. In order to describe the characteristics 
of all eligible studies, the following information were extracted for each study: 
first author, year of publication, geographic region, study size, method of HPV 
detection, HPV types detected and HPV status overall and when available, 
according to gender, smoking status, tumor stage and histology.
Pooled analysis data collection
Following Institutional Review Board approval, invitations to participate in the 
pooled analysis were prepared for the principal investigators of the 81 eligible 
studies. Invitations were not successfully sent to investigators of 13 studies 
due to inactive or unavailable contact information. Although no response or 
a refusal to participate was received from 47 studies, only 41 were excluded 
because 6 of these studies reported individual-level data in the publications. 
Datasets with age, gender, tumor stage, smoking status, histological type and 
HPV results were created for each of these studies and were included in the 
pooled analysis (8,9,26,38,45–47). In total, 27 studies were included in the 
pooled analysis (8,9,11,13,14,26,31,32,34,38,45–60) including the studies of 
E.Taioli et al. and A.Zaravinos et al. (unpublished results).
Verification of cancer diagnosis was reported in the corresponding 
publications for 21 of the 27 studies (8,9,11,13,14,26,34,38,45–50,53–
60). If not explicitly stated in the published article, authors were con-
tacted to clarify what, if any, efforts were made to avoid contamination. 
Efforts to avoid contamination were reported for 22 of the 27 studies 
Fig. 1. Flow diagram summarizing the identification and selection process of eligible studies for inclusion in the pooled analysis.
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(8,9,11,13,26,31,32,34,38,45–48,50–52,54–56,58,59) and for E.Taioli et  al. 
and A.Zaravinos et al. (unpublished results), and all studies reported the inclu-
sion of internal quality controls and/or positive and negative HPV controls. 
From the pooled dataset, 65 cases were excluded: 51 because of inadequate 
DNA based on quality control checks performed by the submitting investigator 
(54), 2 because they were duplicate samples (A.Zaravinos et al., unpublished 
results) and 12 because they were metastasis to the lung (13,57,59,60). The 
pooled analytic dataset included 3249 cases.
Published abstracts and unpublished studies
For E.Taioli et al. (unpublished results; n = 69), all cases were histologically 
confirmed lung cancer patients diagnosed at New York University (NYU)-
Bellevue Hospital from 1993 to 1999. The central pathology registry at NYU-
Bellevue Hospital was used to identify all consecutive African American cases; 
clinical charts were then retrieved using the pathology report number, and per-
sonal/behavioral information was collected. The pathologist reviewed all the 
tissue blocks to make sure that a block containing material from the primary 
lung tumor was used for testing. DNA from formalin-fixed paraffin-embedded 
(FFPE) tissues was extracted and tested for HPV, and physical status was deter-
mined for all HPV16-positive samples. For A.Zaravinos et al. (unpublished 
results; n = 17), all cases were histologically confirmed lung cancer patients 
diagnosed at the Department of Surgical Pathology of the University of Crete 
from 2007 to 2011. About 5–10 serial tissue sections of 10 µm were cut from 
each FFPE block and stained with hematoxylin and eosin (H&E) before micro-
scopic examination. When the proportion of tumor cells was >70%, the FFPE 
block was subjected to DNA extraction. Data from Mehra et al. (32) (n = 62) 
were published in the 2013 Proceedings of the American Association for 
Cancer Research. All cases were a convenience sample of randomly selected 
histologically confirmed lung cancer patients (enriched for non-smoking 
status and adenocarcinoma) diagnosed at Fox Chase Cancer Center (FCCC) 
from 1993 to 2010. FFPE tissues and corresponding demographic and clini-
cal information were obtained from the FCCC Biosample Repository. DNA 
from tumor tissue was extracted and tested for HPV, and physical status was 
determined for all HPV16-positive tumor tissues. Data from Pillai et al. (31) 
(n = 208), were published in the 2013 Proceedings of the American Society of 
Clinical Oncology. All cases were histologically confirmed surgically resected 
lung cancer patients diagnosed at Wellstar Health Systems, Atlanta, GA, from 
2002 to 2008. The samples were consecutively acquired paraffin-embedded 
tissues, archived in a temperature controlled storage area until ready for analy-
sis. Details of the tissue acquisition have been described previously (61). DNA 
from FFPE tissues was extracted and tested for HPV, and physical status was 
evaluated for all HPV16-positive tissues.
HPV detection and genotyping
The HPV testing for the published abstracts and unpublished dataset (E.Taioli 
et al., unpublished results) was performed in a single laboratory. DNA was 
extracted from FFPE lung cancer tissues using ArchivePure DNA purification 
kit (5 Prime). DNA concentration and quality checks were performed by evalu-
ating 260:280 ratios as well as PCR amplification of a β-globin amplicon using 
the RS 42 and KM 29 primers. For the E.Taioli et al. (unpublished results) 
samples, HPV status was determined by nested HPV PCR reactions using 
PGMY09/11, followed by GP5+/GP6+ primers. Briefly, 20 µl PCR ampli-
fications were performed using a GeneAmp PCR System® 9700 (Applied 
Biosystems, Life Technologies) at 95°C for 9 min, 40 cycles of 95°C for 30 s, 
55°C for 1 min and 72°C for 10 min with a final extension of 72°C for 5 min. 
The nested PCR reaction was performed by prediluting 1:100 PCR products 
from the initial reaction in a final reaction volume of 25 µl. The cycling condi-
tions were 95°C for 10 min, 40 cycles of 95°C for 1 min, 55°C for 1 min and 
72°C for 1 min, followed by a final extension at 72°C for 5 min. Negative and 
positive controls were included in each PCR reaction. The PCR products were 
separated in 2% agarose gel by electrophoresis and HPV genotyping of positive 
samples were performed using the Linear Array HPV Genotyping kit (Roche 
Diagnostics) according to the manufacturer’s instructions. For the Mehra et al. 
and Pillai et al. samples, HPV testing was performed using the INNO-LiPA 
genotyping Extra Amplification and Genotyping Extra kits (Innogenetics, 
Belgium). The SPF10 PCR primers are capable of identifying a broad spec-
trum of HPV genotypes by amplifying a 65 bp target in the HPV L1 sequence. 
Genotyping of positive HPV samples was performed using the LiPA genotyp-
ing protocol that involves a reverse hybridization line probe assay to detect 18 
high-risk types (16,18,26,31,33,35,39,45,51–53,56,58,59,66,68,73,82), 7 low-
risk types (6,11,40,43,44,54,70) and additional types (69,71,74). Negative and 
positive controls (HPV6), as well as an internal control (HLA-DPB1 gene), 
to confirm DNA quality and the absence PCR inhibitors, were included in 
the assay.
HPV testing for the second unpublished study was performed by the sub-
mitting investigator (A.Zaravinos et  al., unpublished results). Lung cancer 
tissue sections (FFPE) were deparaffinized with xylene and ethanol washes, 
treated with protease and then DNA from tumor tissue was extracted using the 
QIAmp DNA minikit (Qiagen, Valencia, CA) according to the manufacturer’s 
instructions. Briefly, tissue sections were digested with 0.1 mg/ml proteinase 
K (Promega, Madison, WI) and 400 µl of digestion buffer containing 150 mM 
NaCl, 400 mM Tris–HCl, 60 mM ethylenediaminetetraacetic acid and 15% 
sodium dodecyl sulfate, pH 8.0, in a 1.5 ml eppendorf tube. Samples were 
then incubated at 60°C for 2 days. Fresh proteinase K was added three times 
daily. The samples were extracted once with phenol/chloroform and once with 
chloroform. DNA was precipitated by the addition of 20 µl of 5 M NaCl and 
1 ml of ethanol, recovered by centrifugation for 15 min, washed once with 
cold 70% ethanol and resuspended in 50 µl of double distilled water. DNA 
concentration was calculated using the NanoDrop™ 1000 Spectrophotometer. 
Specimens were examined for the presence of amplifiable DNA using a set 
of primers for the β2-microglobulin gene. Amplification of HPV DNA in the 
specimens was performed by PCR using specific primer pairs for each E6 gene 
region of the HPV6, -11, -16, -18 and -33 subtypes. The samples were initially 
examined for the presence of non-type-specific HPV DNA using the general 
HPV primers, GP5+/GP6+. The following PCR amplification cycling condi-
tions were used: 94°C for 4 min; 40 cycles, 94°C for 1 min, 40°C for 2 min 
and 72°C for 1–5 min. The last cycle was extended by a 4 min elongation at 
72°C. Appropriate negative and positive controls were included in each PCR 
reaction in order to exclude contamination events and to establish the speci-
ficity of primer-directed amplification. Recombinant plasmids carrying HPV 
type-specific sequences served as positive controls for HPV6, -11, -16, -18 and 
-33 genomes detection. For the general screening of HPV DNA, HeLa cells 
transfected with conserved L1 sequences among HPV strains were used as 
the positive control. PCR was carried out in a total volume of 25 µl contain-
ing 5 mM of 5× Green GoTaq reaction buffer, 1.5 mM MgCl2, 0.2 mM of each 
deoxynucleotide triphosphate (dNTPs), 0.6 U of GoTaq Flexi DNA polymer-
ase (Promega) and 200 ng of genomic DNA. The PCR products were examined 
by electrophoresis on a 2% agarose gel and photographed on an ultraviolet 
light transilluminator. The sensitivity of the PCR assay was determined by 
applying a serial-dilution amplification assay of viral-positive control DNA.
HPV physical status
The physical status of HPV16 was assessed in HPV16-positive lung cancer 
tissues for three published studies that were included in the pooled analy-
sis (32,48,49) using the same quantitative PCR assay as described previ-
ously (62). Each HPV16 DNA-positive sample was amplified for 76 bp of 
the E2 gene using the following primers: forward 5′-AACGAAGTATCC 
TCTCCTGAAATTATTAG-3′ (3361–3389 nt); reverse 5′-CCAAGGCG 
ACGGCTTTG-3′ (3427–3443 nt), as well as 81 bp of the E6 gene, prim-
ers forward 5′-GAGAACTGCAA TGTTTCAGGACC-3′ (94–116 nt); 
reverse 5′-TGTATAAGTTGTTTGCAGC TCTGTGC-3′ (150–169 nt), 
in the presence of specific hybridization probes for E2-(FAM-CACCC 
CGCCGCGACCCATA-TAMRA) (3406–3424 nt) and E6-(FAM-C 
AGGAGCGAC CCAGAAAGTTACCACAGTT-TAMRA) (119–147 nt). The 
cycling conditions were 2 min at 50°C, 10 min at 95°C, and a two-step cycle of 
95°C for 15 s and 60°C for 60 s for a total of 40 cycles. A standard curve was 
generated from 8-fold serial dilution of p1203 PML2d HPV16 (Addgene plas-
mid 10869, deposited by Peter Howley, MD; Addgene, Cambridge, MA). Both 
HPV16-positive cell lines, SiHa and Caski DNA were included as controls. 
The assay was performed in duplicate for each sample. Physical status was 
determined by calculating the ratios of E2 to E6 where a ratio <1.0 indicates 
a predominance of integrated HPV genomes, >1.0 indicates a predominance 
of episomal genomes. The results were recorded as copy numbers per 20 ng 
of DNA.
Statistical analysis
All statistical analyses were carried out using SAS 9.3 (SAS Institute, Cary, 
NC) with a significant level of 0.05 and evaluation of publication bias was per-
formed using the Comprehensive Meta Analysis Version 2 software (Biostat, 
Englewood, NJ). The adjusted HPV prevalence of each region was calculated 
after adjusting for age, gender, smoking history, tumor stage and study and 
reported as an estimated probability of HPV-positive lung cancer patients with 
95% confidence intervals (CIs). Random effects logistic regression models 
were used to determine the association between HPV16/18 status and clinical 
and demographic variables. Study was used as a random effect to allow devia-
tion caused by different study conditions. In the international pooled dataset, 
one out of three of the subjects was missing either smoking history or tumor 
stage. Both variables, we believe, are important in understanding the nature of 
HPV16/18 prevalence. However, exclusion of subjects with missing values is 
inefficient and can lead to biased results if those dropped are atypical in some 
respect. Therefore, multiple imputations were performed prior to regression 
analyses using IVEware. Ten imputation datasets were generated and final 
model estimates were combined using SAS 9.3. For each imputed dataset, the 
missing values were drawn from other observed data (63). The uncertainty 
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about the correct model for non-response was captured by the variance across 
multiple imputed datasets. Subjects with one or part of the covariates miss-
ing were included in the analysis and hence, no information was lost due to 
exclusion.
Results
Twenty-seven of the 81 eligible studies elected to participate in this 
pooled analysis and the resulting pooled dataset included 3249 cases, 
whereas the remaining 54 studies had 4199 cases. Detailed characteristics 
of each study in the pooled dataset are summarized in Table I. 
The majority of cases in the pooled dataset were from Asia (40%, 
1312 cases) and Europe (34%, 1100 cases). North/South American 
studies represented 26% of all cases in the pooled dataset (n = 837). 
For the non-included studies, the majority of cases were also from 
Asia (55%, 2332 cases) and Europe (33%, 1404 cases), whereas 7% 
of cases (n = 299) were from North/South America and 4% (n = 164 
cases) from other geographic regions (Australia and the Middle East). 
The size of studies in the pooled dataset varied from 17 to 399 cases, 
whereas the non-included study sizes ranged from 5 to 319 cases. 
Table I. Characteristics of studies included in the pooled analysis and adjusted HPV prevalence
Study Tissue source Method of HPV detection Histological type HPV types detected
Asia (N = 1312)
 Baba et al. (N = 77) (49) FFPE PCR (SPF10, Inno-LIPA) AC, SCC HPV 6, 16, 18, 33
 Kinoshita et al. (N = 34) (57) FF PCR (TS: HPV 16, 18, 33) AC, SCC, ASqa, LCCa, SmCCa HPV 18
 Iwakawa et al. (N = 275) (53) FF PCR (TS: HPV 16, 18, 33) AC HPV negative
 Hiroshima et al. (N = 49) (52) FFPE PCR (TS: HPV 16, 18, 33) AC, SCC HPV 16
 Goto et al. (N = 296) (51) FFPE PCR GP5+/GP6+ AC, SCC, CSrca HPV 6, 11, 16, 18
 Lim et al, 2009 (N = 99) (56) FFPE ISH (HPV6, 11, 16, 18, 31,  
33, 35, 45, 51, 52, 56, 58, 66)
AC HPV negative
 Miyagi et al. (N = 176) (8,9) FFPE PCR (TS: HPV 6, 11, 16, 18) AC, SCC HPV 6, 11, 16, 18
 Hirayasu et al. (N = 73) (26) FFPE PCR (TS: HPV 6, 11, 16, 18) SCC HPV 6, 16, 18
 Wang et al. (N = 210) (58) FFPE, Bxb, PEb PCR (MY09/MY11 and TS: HPV 
16, 18)
AC HPV16, HPV18
 Tsuhako et al. (N = 23) (47) FFPE PCR (TS: HPV 6, 11, 16, 18) ASq HPV 6, 11, 16, 18
 Adjusted HPV 16/18 prevalence (95% CI)c = 4.60% (3.48, 5.73)
 Adjusted HPV 16 prevalence (95% CI)c = 1.49% (0.86, 2.11)
 Adjusted HPV 18 prevalence (95% CI)c = 1.09% (0.66, 1.52)
Europe (N = 1100)
 Syrjanen et al. (N = 131) (14) FFPE ISH (HPV6, 11, 16, 18, 30) SCC HPV 16, Xd
 Syrjanen et al. (N = 77) (55) FFPE PCR (MY09/MY11/GP5+/GP6+) AC, SCC, other HPV 6, 16
 Giuliani et al. (N = 77) (13) FFPE and FF PCR (MY09/MY11/GP5+) AC, SCC, ASqa, LCCa, 
SmCCa, NSCLCa, othera
HPV 6, 16, 18, 31, 53,
 Gorgoulis et al. (N = 68) (11) FFPE and FF PCR (MY09/MY11/GP5+/GP6+) AC, SCC, LCCa HPV negative
  Zaravinos et al. (unpublished 
results, N = 17)
FFPE PCR (GP5+/GP6+) ACe, SCCe, LCCa, NSCLCa HPV negative
 Koshiol et al. (N = 399) (54) FFPE PCR (TS: HPV 16, 18; SPF10 
primers (n = 92)
AC, SCC, LCC, SmCC, other HPV 16, 18
 Carpagnano et al. (N = 89) (34) FFPE and BBb PCR (consensus HPV primers) AC, SCC, SmCC HPV 16, 30, 31, 39,
 Nuorva et al. (N = 22) (46) FFPE PCR (MY09/MY11) AC HPV 6, 11, 16, 18, 31, 33
 van Boerdonk et al. (N = 220) (59) FFPE PCR (GP5+/GP6+) AC, SCC, LCC, NSCLCe HPV negative
 Adjusted HPV 16/18 prevalence (95% CI)f = 3.03% (2.76, 3.30)
 Adjusted HPV 16 prevalence (95% CI)f = 2.94% (2.68, 3.21)
 Adjusted HPV 18 prevalence (95% CI)f = 0.82%(0.73, 0.92)
South and Central America (N = 105)
 Castillo et al. (N = 36) (50) FFPE PCR (GP5 + 6+) and SB AC, SCC, SmCCe HPV 16, 18, 33
 Aguayo et al. (N = 69) (48) FFPE PCR (GP5+/GP6+) and SB AC, SCC HPV 6, 16, 18, 31, 45
 Adjusted HPV 16/18 prevalence (95% CI)f= 21.90% (19.61, 24.20)
 Adjusted HPV 16 prevalence (95% CI)f = 19.18% (16.88, 21.49)
 Adjusted HPV 18 prevalence (95% CI)f = 7.78% (6.61, 8.95)
North America (N = 732)
  Taioli et al. (unpublished results, 
N = 69)
FFPE PCR (PGMY09/PGMY11/ 
GP5+/6+)
AC, SCC, LCCa, NSCLCa, 
othere
HPV 51, X
 Pillai et al. (N = 208) (31) FFPE PCR (SPF10, Inno-LIPA) AC, SCC, ASqe, LCC, othere HPV 6, 16, 18, 39, 53, X
 Mehra et al. (N = 62) (32) FFPE PCR (SPF10, Inno-LIPA) AC, SCCe, ASqa, LCCa, HPV 6, 16, 18, 52, 53, 44, 
68, 39, 74, 82, X
 Joh et al. (N = 29) (38) FF PCR (GP5+/GP6+) AC, SCCe, LCCa, NSCLCa HPV 11, 16
 Yanagawa et al. (N = 330) (60) FFPE PCR (GP5+/GP6+) and ISH AC, SCC HPV negative
 Bohlmeyer et al. (N = 34) (45) FFPE PCR (MY09/MY11) SCC HPV 18
Adjusted HPV 16/18 prevalence (95% CI)f = 3.78% (3.35, 4.22)
Adjusted HPV 16 prevalence (95% CI)f = 2.03% (1.68, 2.39)
Adjusted HPV 18 prevalence (95% CI)f = 2.49% (2.23, 2.75)
Other: histological type, not otherwise specified. AC, adenocarcinoma; ASq, adenosquamous carcinoma; BB, bronchial brushing; Bx, biopsy tissue; CSrc, 
carcinosarcoma; FF, fresh frozen; ISH, in situ hybridization; LCC, large cell carcinoma; NSCLC, non-small-cell lung carcinoma, not otherwise specified; PE, 
pleural effusion; SB, Southern blot; SmCC, small cell carcinoma; TS, type-specific primers.
aNumber of cases ≤6.
bCancer cells present and confirmed by pathologist.
cStudy is included in the model as a random effect.
dType not defined; HPV+ (for the HPV6/11/16/18/30 panel).
eNumber of cases 7–10.
fStudy is included as a covariate in the model.
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All studies included in the pooled analysis performed HPV DNA 
testing on surgical tissue (FFPE and/or frozen) or biopsy specimens. 
Similarly the non-included studies performed HPV DNA testing 
on surgical or biopsy tissue specimens except for one study which 
utilized bronchial aspirates from lung cancer patients (64). Most of 
the studies in the pooled analysis as well as the non-included stud-
ies used PCR-based methods for HPV DNA detection, 93 and 80%, 
respectively. Although adenocarcinoma and SCC were the most com-
mon histological types included in the pooled dataset (56%, 1808 
cases and 38%, 1220 cases, respectively) and in the non-included 
studies (33%, 1404 cases and 57%, 2379 cases, respectively), the 
pooled analysis consisted of a larger proportion of adenocarcinoma 
cases compared with the non-included studies. Similar proportions of 
other histological types were represented in both the pooled dataset 
and non-included studies (7%, 214 cases and 8%, 350 cases, respec-
tively). Histology was not specified for 7 (0.2%) cases in the pooled 
dataset and for 68 (1.6%) cases in the non-included studies.
The predominant high-risk HPV types found in lung cancer 
patients were HPV 16 and HPV18 (Table I). Other high-risk HPV 
types (HPV31, 33, 35, 45, 51, 52, 68 and 82) were also detected. For 
all geographic regions (Asia, Europe as well as North America) and 
with the exception of South and Central America, large-to-moderate 
heterogeneity was observed between the studies with no evidence of 
publication bias (data not shown). In order to address the heteroge-
neity, HPV prevalence rates were calculated after adjusting for age, 
gender, smoking history and tumor stage; study was included as a 
random effect where appropriate (Table I). Significant differences in 
HPV16/18 prevalence were noted between geographic regions. HPV 
16/18 was most prevalent in South and Central America (adjusted 
prevalence [AdjPr]  =  21.90%, 95% CI  =  19.61–24.20), followed 
by Asia (AdjPr  =  4.60%, 95% CI  =  3.48–5.73), North America 
(AdjPr = 3.78%, 95% CI = 3.35–4.22) and Europe (AdjPr = 3.03%, 
95% CI = 2.76–3.30). For each geographic region, the prevalence of 
HPV16 was significantly higher than HPV18, with the exception of 
North America and Asia. South and Central America had the highest 
prevalence of HPV16 followed by Europe, North America and Asia, 
whereas HPV 18 was also highest in South and Central America, fol-
lowed by North America and Asia. There was virtually no HPV 18 
detected in European patients (AdjPr = 0.82%, 95% CI = 0.73–0.92).
Clinical and demographic characteristics of HPV16/18-positive 
lung cancer cases
The mean age of all lung cancer patients in the pooled dataset was 
65.0 ± 10.1 (SD) years. The demographic and clinical characteristics 
for all cases are presented in Table II; comparisons were made between 
North American cases and the rest of the world. For the studies con-
ducted in North America as well as the rest of the world, a higher 
proportion of the patients were male (53 and 72%, respectively), ever 
smokers (84 and 76%, respectively) and most of the lung cancers were 
not SCC (64 and 62%, respectively). North American patients were 
mostly White (89%) in contrast to the rest of the world where the 
majority were non-White (57%). Early-stage lung cancers were more 
represented in the North American studies (63%) in contrast to only 
50% in studies from the rest of the world. For each geographic sub-
group, there were no noted differences in the proportion of HPV16/18 
patients according clinical and demographic characteristics with the 
exception of race. The majority of patients in North America were 
White and a higher proportion of HPV 16/18-positive lung cancers 
were also noted among White patients (72%). However, for the rest of 
the world, although a near equal proportion of White and non-White 
patients were included, the majority of HPV 16/18-positive lung can-
cers were observed in non-White patients (88%).
No statistically significant associations were observed between 
HPV16/18-positive lung tumors and gender, age, smoking history, 
stage and histology (Table III). However, HPV 16/18-positive lung can-
cer cases were less likely to be observed among White patients com-
pared with non-White patients (adjusted odds ratio [Adj OR] = 0.33, 
95% CI = 0.12–0.90). For larger studies, (≥100 cases, 4 studies with 
a minimum of 131 cases and a maximum of 399 cases), the associa-
tion of HPV 16/18 with race persisted (White: Adj OR = 0.08, 96% 
CI = 0.02–0.33). For smaller studies (<100 cases, 16 studies with a min-
imum of 22 cases and a maximum of 99 cases), the HPV 16/18-positive 
Table II. Comparisons of demographic characteristics of patients according to HPV16/18 status (published datasets only)
Characteristic Asia, Europe and South/Central America North America
Total (N = 2500) HPV16/18 
positive 
(N = 233, 
9.3%)
HPV16/18 
negative 
(N = 2267, 
90.7%)
P valuea Total (N = 663) HPV16/18 
positive 
(N = 23, 
3.5%)
HPV16/18 
negative 
(N = 640, 
96.5%)
P valuea
Gender 0.157 0.632
 Male 1749 (71.92) 154 (66.96) 1595 (72.43) 349 (52.64) 10 (43.48) 339 (52.97)
 Female 683 (28.08) 76 (33.04) 607 (27.57) 314 (47.36) 13 (56.52) 301 (47.03)
Age (years) 0.529 0.557
 ≤66 1212 (51.33) 92 (42.4) 1120 (52.24) 315 (47.51) 10 (43.48) 305 (47.66)
 >66 1149 (48.67) 125 (57.6) 1024 (47.76) 348 (52.49) 13 (56.52) 335 (52.34)
Race 0.059 0.102
 White 1083 (43.32) 27 (11.59) 1056 (46.58) 239 (88.52) 13 (72.22) 226 (89.68)
 Othersb 1417 (56.68) 206 (88.41) 1211 (53.42) 31 (11.48) 5 (27.78) 26 (10.32)
Smoking history 0.762 0.256
 Never smoked 602 (24.06) 67 (28.93) 534 (23.56) 104 (15.69) 3 (13.04) 101 (15.78)
 Ever smoked 1898 (75.94) 166 (71.07) 1733 (76.44) 559 (84.31) 20 (86.96) 539 (84.22)
Histology 0.536 0.345
 SCC 953 (38.12) 107 (45.92) 846 (37.32) 239 (36.43) 5 (22.73) 234 (36.91)
 Othersc 1547 (61.88) 126 (54.08) 1421 (62.68) 417 (63.57) 17 (77.27) 400 (63.09)
Stage 0.614 0.099
 0/Id 1240 (49.60) 108 (46.52) 1132 (49.92) 422 (63.63) 15 (65.65) 407 (63.59)
 II 460 (18.41) 36 (15.41) 424 (18.72) 106 (16.01) 1 (5.59) 105 (16.39)
 III 479 (19.14) 43 (18.37) 436 (19.22) 109 (16.43) 3 (13.91) 106 (16.53)
 IV 321 (12.84) 46 (19.70) 275 (12.14) 26 (3.93) 4 (16.52) 22 (3.48)
Data are presented as number of patients (%).
aP value was calculated by a logistic regression model with study as a random effect.
bOthers include Black, Hispanic, Asian and race not specified.
cOthers include adenocarcinoma and histology not specified.
dIncludes four cases with stage 0 (in situ).
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patients were more likely to be female (Adj OR = 1.61, 95% CI = 1.00–
2.59), older than 66 years (Adj OR = 1.65, 95% CI = 1.05–2.59) and 
diagnosed with stage IV tumors than stage I/II (Adj OR = 2.55, 95% 
CI = 1.08–6.04). There were no differences in the association of HPV 
with stage IV tumors when we compared studies that reported verifi-
cation of cancer diagnosis to those that did not report verification of 
cancer diagnosis in their publication. Similarly, for studies that reported 
efforts to avoid contamination, there was no difference in the associa-
tion of HPV16/18 with stage IV tumors compared with those stud-
ies that did not include this information in their publication (data not 
shown). When North American studies were evaluated separately, there 
was no association of HPV 16/18 with gender, age, smoking history or 
histology and a marginal association with race was observed, which 
was significant for larger studies only (data not shown).
HPV prevalence in normal versus lung cancer tissues
There were 16 studies that evaluated HPV prevalence in lung can-
cer tissues (1208 cases) in addition to normal lung tissues (732 con-
trols). Normal lung tissues were either from lung cancer patients (i.e. 
adjacent normal or non-adjacent normal, n  =  255) or from normal 
lung tissues from non-cancer patients (n = 477). Lung cancer tissues 
were almost four times more likely to be positive for any HPV DNA 
compared with normal (OR = 3.86, 95% CI = 2.87–5.19; study was 
included as a random effect).
Evidence of HPV16/18 DNA integration in lung cancer
Because integration of high-risk HPV DNA correlates with the over-
expression of HPV oncogenes, we investigated the physical status 
of HPV16 in a subset of cases. In our pooled international dataset, 
physical status data were available for three studies conducted in 
Asia, South/Central America and North America (32,48,49) (n = 28, 
HPV16-positive patients). For the HPV16-positive lung tumors, 75% 
(21/28) carried integrated HPV16 genomes, 3.6% (1/28) carried epi-
somal HPV16 genomes and 21.4% (6/28) carried both integrated and 
episomal forms of HPV16 DNA. There was no significant difference 
in the distribution of HPV physical status according to each study 
(P = 0.436).
An equal number of male and female patients were HPV16 posi-
tive, but the majority of female patients, i.e. 92.9% (13/14), carried 
integrated HPV 16 DNA compared with 57% (8/14) of male patients 
(Table IV). None of the female patients had episomal HPV genomes 
in their tumors and only 7.1% (1/14) had both integrated and episomal 
forms. On the other hand, 7.1% (1/14) of male patients had episomal 
HPV genomes, and 35.7% (5/14) had both integrated and episomal 
HPV genomes in their tumors.
Survival analysis
A subset of patients had available follow-up data for four published 
studies (11,31,55,56) (n = 451). For all patients combined, the 2 year 
and 5 year overall survival rates for HPV16/18-negative patients were 
60.9 and 38.5%, respectively, whereas the 2 year and 5 year overall 
survival rates for HPV16/18-positive patients were 71.4 and 64.3%, 
respectively. The Kaplan–Meier curves according to HPV16/18 status 
(data not shown) were not statistically significantly different (log-rank 
P value = 0.263).
Discussion
To date, >100 studies (including case reports) have analyzed HPV 
DNA in lung cancers (7). Although the majority of these studies have 
reported the prevalence of HPV16 and/or 18 DNA and a few publica-
tions have shown evidence of HPV oncogene (E6 and E7) expres-
sion (12,57), definite evidence of a causal relationship is still missing. 
Previously published meta-analyses of HPV in lung cancer show that 
HPV16 and HPV18 are the two most common genotypes detected in 
lung tumors worldwide (5–7); however, the characteristics of patients 
with these tumors were not determined. This study is the first inter-
national pooled analysis of individual data received from various 
research groups and was focused to define the demographic, behavio-
ral and clinical characteristics of lung cancer cases with HPV16 and/
or 18 DNA. We have also for the first time reported and compared 
published data from five North American studies with other parts 
of the world. Similar to previous reports, as expected, in our study 
(5–7), HPV16 and/or 18 were the most prevalent high-risk genotypes 
Table III. Association of demographic and clinical variables with HPV 16/18 (published datasets only in all regions)
Variable HPV16/18 positive
All studies (N = 3163) Small studiesa (N = 918) Large studiesb (N = 2245)
ORc (95% CI) P value ORc (95% CI) P value ORc (95% CI) P value
Gender 0.141 0.049 0.824
 Male 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
 Female 1.27 (0.92, 1.75) 1.61 (1.00, 2.59) 1.05 (0.68, 1.62)
Age (years) 0.420 0.029 0.361
 ≤66 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
 >66 1.13 (0.84, 1.54) 1.65 (1.05, 2.59) 0.82 (0.54, 1.25)
Race 0.029 0.708 < 0.001
 Othersd 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
 White 0.33 (0.12, 0.90) 0.80 (0.25, 2.59) 0.08 (0.02, 0.33)
Smoking history 0.930 0.859 0.974
 Never smoked 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
 Ever smoked 1.02 (0.66, 1.57) 1.06 (0.58, 1.91) 1.01 (0.59, 1.74)
Histology 0.812 0.576 0.827
 Otherse 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
 SCC 1.05 (0.71, 1.54) 1.16 (0.69, 1.93) 0.94 (0.53, 1.66)
Tumor stage 0.561 0.044 0.338
 I/II 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
 III 0.87 (0.56, 1.37) 0.94 (0.53, 1.66) 0.78 (0.36, 1.68)
 IV 1.10 (0.66, 1.85) 2.55 (1.08, 6.04) 0.68 (0.36, 1.27)
Ref.: reference level.
aSmall studies include studies with 22 ≤ number of cases ≤ 99.
bLarge studies include studies with 131 ≤ number of cases ≤ 399.
cStudy was included as a random effect.
dOthers include Asian, Black, Hispanic and race not specified.
eOthers include adenocarcinoma and histology not specified.
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detected in lung cancers, but still counting for a low fraction of lung 
cancers and with heterogeneity among studies.
It is plausible that differences in the geographic location, study size, 
demographic and clinical makeup of each study could contribute to 
heterogeneity in HPV prevalence between studies. Furthermore, the 
majority of studies included in this pooled analysis were small (<100 
cases) and may be less representative samples, thus contributing to 
heterogeneity in HPV prevalence. Therefore, for each geographic 
region, the prevalence of HPV 16/18 was adjusted for each study 
as well as potential confounders yet variations in HPV16/18 preva-
lence remained. The highest prevalence of HPV16/18-positive lung 
cancers was observed in South and Central American, whereas North 
American and Asian studies had similar prevalence and European 
studies had significantly lower prevalence of HPV 16/18. Similar 
observations were made for HPV 16 and HPV 18 independently. 
However, within each geographic region, distinct differences in the 
prevalence of HPV 16 and HPV18 genotypes were noted with the 
exception of Asia and North America. In North America, although the 
prevalence of each genotype was low, the prevalence of HPV 18 was 
slightly higher than that of HPV 16. In contrast, for Asia, Europe and 
South and Central America, if any HPV DNA detected in lung cancer, 
HPV 16 appeared to be more prominent than HPV18. In Europe, the 
prevalence of HPV18 was near zero. Factors that may be responsible 
for variability in HPV prevalence could be sexual behaviors of partici-
pants, genetics and possible environmental contamination as argued 
in the study by Koshiol et al.  (54).
In addition to geographic location, the recent meta-analysis by 
Syrjanen et  al. (7) reported that the heterogeneity between studies 
might be related to differences in histologic type. In this study, there 
were no differences in the proportion of histologic types in North 
America compared with the rest of the world and we observed no 
association of HPV 16/18 status with histology. Although South and 
Central American studies had the highest HPV prevalence, there were 
only two studies from this region; therefore, this finding will need 
to be confirmed by additional studies. Second to South and Central 
America, we observed that Asia had the highest prevalence of HPV 
16 and 18. A  significant association of HPV 16/18 DNA was also 
observed with race, where non-White lung cancer patients were more 
likely to have HPV-positive tumors compared with White lung cancer 
patients. There may be a number of reasons for this observed differ-
ence in HPV prevalence some of which might include differences in 
sexual practices or differences in susceptibility. Further investigation 
of the potential reasons for the racial difference in the association of 
HPV16/18 is needed.
Park et al. (65) evaluated HPV status in 112 non-small-cell lung 
cancer patients from Korea and reported that HPV16 was more com-
mon in younger lung cancer patients and HPV18 was more common 
in patients diagnosed with advanced stage. Although we categorized 
HPV16 and HPV18-positive tumors into a single group, we found no 
associations with age or stage, neither for gender, smoking history 
or histology. However, for small studies only, HPV16/18 was associ-
ated with old age (>66 years), female gender and advanced stage. It is 
possible that patients with metastatic disease (by definition, stage IV) 
could include metastases from other or mixed tumors, such as head 
and neck or cervical cancers (59), and the resulting misclassification 
could account for some of these findings. Therefore, the association 
with older females with stage IV tumors warrants further investigation 
in a single, larger and more representative study.
Although HPV-positive oropharyngeal cancers have been found 
to be associated with non-smokers, these tumors are also associ-
ated with patients having lower number of pack-years of cigarettes 
compared with heavy smokers (66). In vitro studies also show that 
tobacco smoke carcinogens have been shown to increase HPV16 and 
18 viral synthesis as well as interact with HPV16 E6/E7 oncoproteins 
to increase lung cell proliferation (67). Furthermore, smoking sup-
presses the host innate immunity including functional and structural 
changes in the respiratory ciliary epithelium, lung surfactant protein 
and immune cells in the lung (68), thus may facilitate HPV infection 
and persistence in the lung in a subset of tumors. Mechanistically, it is 
not yet clear how HPV might promote lung carcinogenesis; however, 
the cooperation between HPV and tobacco smoke carcinogens for 
lung carcinogenesis is plausible. In this study, the association of HPV 
with smoking status was not conclusive. Therefore, further studies are 
needed to investigate the relationship between HPV and smoking sta-
tus among patients with HPV-positive lung tumors.
Although our study cannot conclusively confirm the carcinoge-
netic role of HPV in lung cancer, we have shown that lung cancer 
tissues were almost 4-fold more likely to be HPV-positive compared 
with normal lung tissues. Secondly, our preliminary investigation of 
HPV16/18 physical status among a subset of tumors shows that the 
majority of the female tumors carried integrated HPV DNA while the 
physical status of HPV16/18 in male tumors was inconsistent. Given 
the predominance of integrated HPV genomes in female lung can-
cer patients, it is possible that HPV may play a role in lung cancer 
development but is unlikely to contribute to a large proportion of lung 
cancer cases. Although the presence of integrated DNA would sug-
gest that the DNA detected was not simply due to contamination, it is 
important to note that there are no published studies comparing E2/
E6-based integration with direct integration detection methods, which 
are more reliable. Thus, the results must be interpreted with caution. 
Our findings suggest an association of HPV DNA with a small frac-
tion of lung tumors, with large geographic variations, but further 
comprehensive analysis is needed to assess whether this association 
reflects a causal relationship. Such detailed analysis should include 
not only HPV DNA testing but evaluation of all criteria that were 
postulated to prove a causal involvement of HPV in carcinogenesis, 
such as p16 expression and HPV E6/E7 oncogene expression (2,69), 
and measures to exclude pulmonary metastases (59).
The survival data in this pooled analysis only included 14 
HPV16/18-positive cases and 5 events, and there were no signifi-
cant differences between the Kaplan–Meier curves. However, based 
on the 2 and 5 year survival rates between HPV16/18-positive 
and HPV16/18-negative patients, there was some suggestion that 
HPV16/18-positive lung cancer patients had improved survival. 
This trend toward improved survival is consistent with HPV-related 
Table IV. HPV 16 physical status in primary lung carcinomas
Case Age Sex Histology Physical status
1 69 Female Adenocarcinoma Mixed
2 84 Male Adenocarcinoma Integrated
3 67 Male Adenocarcinoma Integrated
4 74 Male SCC Mixed
5 62 Female Adenocarcinoma Integrated
6 58 Male SCC Integrated
7 66 Female Adenocarcinoma Integrated
8 75 Male SCC Integrated
9 70 Female Adenocarcinoma Integrated
10 72 Female Adenocarcinoma Integrated
11 80 Male SCC Mixed
12 72 Female Adenocarcinoma Integrated
13 55 Female Adenocarcinoma Integrated
14 79 Male SCC Integrated
15 59 Female Adenocarcinoma Integrated
16 74 Female SCC Integrated
17 71 Female Adenocarcinoma Integrated
18 70 Male SCC Mixed
19 74 Male SCC Integrated
20 69 Male Adenocarcinoma Integrated
21 78 Male SCC Mixed
22 68 Male SCC Episomal
23 59 Female Adenocarcinoma Integrated
24 63 Male Adenocarcinoma Integrated
25 69 Female Adenocarcinoma Integrated
26 39 Female SCC Integrated
27 66 Male SCC Mixed
28 62 Female Adenocarcinoma Integrated
SiHa Integrated
Caski Mixed
Mixed: integrated and episomal genomes.
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carcinogenesis in non-cervical sites, such as the head and neck and 
penile cancer, where HPV-positive cancer patients have an improved 
overall and disease-free survival compared with HPV-negative 
patients (70–72). This observation needs to be verified in a much 
larger number of cases/events and adjustment for known prognostic 
factors including a history of HPV-related disease as well as treatment 
for previous HPV-related disease.
The availability of individual data from each study included in the 
analysis reduces the potential errors associated with aggregate data. 
However, a number of limitations are inherent in this study design as 
well. One of these limitations is the lack of a uniform gold standard 
in the HPV DNA detection methods leading to variability in HPV 
prevalence. Only 27 of the 81 eligible studies participate in this analy-
sis. We have compared the characteristics of the cases in the pooled 
dataset and with that of the non-included studies and remain confident 
that both subsets are similar in characteristics. Nevertheless, possible 
selection bias cannot completely be ruled out. Although the overall 
sample size was large, some of the subgroup analyses included small 
numbers. Although this study has good representation of popula-
tions from the Americas, Europe as well as Asia, China, Korea and 
Taiwan were not as well represented. In addition, the North American 
dataset was limited, in that, the majority of cases were of European 
descent; a larger US study with broad ethnic diversity is needed to 
allow for further investigation related to HPV and race. Although the 
present analysis provides evidence in favor of an association of HPV 
DNA with a small subset of lung cancer, these findings need to be 
validated and further comprehensive analysis is needed to examine a 
potential causal relationship. A detailed analysis of a larger and more 
representative case series, including the testing of all criteria that were 
postulated to prove a causal involvement of HPV in carcinogenesis 
and excluding pulmonary metastases, needs to be performed. Most 
importantly, the preliminary evidence on the potential prognostic role 
of HPV in lung cancer needs confirmation because of its potential 
clinical implications, e.g. in therapy of lung cancer.
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